… β-lactamases (ESBLs) is a significant resistance-mechanism that impedes the antimicrobial
treatment of infections … Proper infection control practices and barriers are essential to prevent …

… in the treatment of patients with infections caused … lactamase/β-lactam combinations will
perform as compared to current BAT in the treatment of carbapenem-resistant bacterial infections…

… lactamase inhibitors allows clinicians to rely on the well-tolerated, clinically effective β-lactam
antibiotics to treat a variety of bacterial infections… for the treatment of common infections, …

… of different antimicrobials for infections caused by multidrug-… carbapenems for the treatment
of bloodstream infections (BSI) … efficacious as carbapenems for the treatment of BSI due to …

… Our ability to successfully treat infections due to these increasingly resistant organisms
demands a multifactorial approach combining continued research and development of novel …

… of β-lactamases 7 . Several studies have shown that carbapenem treatment is associated …
-PE infections and remains the “gold standard” treatment for serious and invasive ESBL-PE …

… infection as well as an indirect effect through their ability to produce the enzyme beta-lactamase…
part of the normal flora at the infection site and is often employed it the treatment of other …

… , especially when combined with a β-lactamase inhibitor (see below). … to treat infections
caused by enteric bacteria before the global emergence of extended-spectrum β-lactamases (…

… β-lactamases. Clinical data regarding the potential value of cephamycins for the treatment
of ESBL-associated infections are scarce. Specifically, a small retrospective study evaluated …

… The effect on 30-day mortality of treatment with intravenous beta-lactam/beta-lactamase …
carbapenem in patients with ESBL-producing Enterobacteriaceae bloodstream infections. …